HONG KONG, May 21, 2025 – We are thrilled to announce that today, May 21, 2025, Eagle IP celebrates its 20th anniversary, marking two decades of dedication to client success and innovation in patent law. Founded on May 21, 2005 by Dr. Jacqueline Lui (Jackie), the firm has grown from its humble beginnings into a respected name in the industry.

In a recent team celebration, Jackie, the firm’s founder, shared her reflections on Eagle IP’s journey. “Starting Eagle IP was a leap of faith driven by my commitment to my clients and their patent portfolios,” she said. “Transferring two significant portfolios laid the foundation for the beginnings of the firm and paved the way towards our success. I’m grateful for the perseverance that carried us through tough times. Our CPR culture—caring, professional, and responsive—has defined who we are and will guide us forward.”

The anniversary event highlighted the firm’s strong culture, with team members who have been with the firm for over a decade sharing memories of growth under Jackie’s leadership.

Jennifer Che, current President and Managing Director who “took the baton” of Eagle IP leadership last year from Jackie, expressed her commitment to upholding these values while driving expansion, noting the firm’s increasing client base and active participation in global conferences.

Eagle IP looks to the future with optimism, dedicated to maintaining its high standards, fostering continuous learning, and building stronger team relationships. Jackie and her husband HC Lui emphasized the power of teamwork, assuring continued support as the firm embarks on its next chapter.

A huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我們過去活動

Recommended Insights

China Releases Draft Implementation Guidelines for the Drug Administration Law

2022年6月2日
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 1: Delayed Examination

2024年1月25日
December 2023 appears to have been an exceptionally busy and fruitful month in the China patent space. Following the State Council’s approval of the long-awaited Patent Law Implementation Regulations (“Regulations”, similar to the CFR in the US) in November, the CNIPA finally made public the full text of the Regulations just before the arrival of […]

Chinese Courts Cares More About Patent Quality Now (A Doctrine of Equivalents Story)

2022年12月13日
There is no doubt that the drafting quality of a patent can be crucial in determining the success (or failure!) of the patent during litigation. However, due to various reasons, patents often fail to use the right drafting strategies that best protect the invention. Too often, inexperienced or unsophisticated patent drafters merely listen to an […]

CHINA: New Patent Examination Guidelines Now Available for Public Comment

2021年8月4日
Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses […]
Top crossarrow-right